Chronic heart failure isn’t just a diagnosis; it’s a daily struggle with life-altering consequences. Without timely and effective treatment, patients face relentless fatigue, shortness of breath, repeated hospitalizations, and an alarming risk of early death. And this isn’t a small subset.
Despite the critical nature of heart failure management, a significant gap in care persists.
Only 25% of these patients are prescribed essential medications like ACE inhibitors or ARBs, proven to reduce heart failure symptoms and improve long-term outcomes. This leaves 1.68 million patients in the Essence network who are not receiving the benefits of these potentially life-saving treatments. Despite the critical nature of heart failure management, a significant gap in care persists. Both ARBs and ACEs work by blocking the renin-angiotensin-aldosterone system (RAAS), a key regulator of blood pressure and cardiovascular function. By inhibiting RAAS, these medications help relax blood vessels,
This, in turn, improves heart function and reduces the risk of cardiovascular events, including heart failure hospitalizations, morbidity, and mortality. Studies consistently demonstrate that ARBs and ACE inhibitors can significantly improve the
Through personalized outreach to these targeted patients and their treating providers, pharma can raise awareness about the importance of these treatments and encourage meaningful health encounters between patients and their
By focusing on this underserved patient cohort, we can bridge the gap in heart failure care and ensure that more patients receive the treatments they need to live longer, healthier lives.